Chasov Vitaly, Gilyazova Elvina, Ganeeva Irina, Zmievskaya Ekaterina, Davletshin Damir, Valiullina Aygul, Bulatov Emil
Laboratory of Biomedical Technologies, Institute of Fundamental Medicine and Biology, Kazan Federal University, 18 Kremlyovskaya Street, Kazan 420008, Russia.
Shemyakin-Ovchinnikov Institute of Bioorganic Chemistry, Russian Academy of Sciences, Moscow 117997, Russia.
Biomolecules. 2024 Dec 23;14(12):1653. doi: 10.3390/biom14121653.
Rheumatoid arthritis (RA) is a chronic autoimmune disease that leads to joint inflammation, progressive tissue damage and significant disability, severely impacting patients' quality of life. While the exact mechanisms underlying RA remain elusive, growing evidence suggests a strong link between intestinal microbiota dysbiosis and the disease's development and progression. Differences in microbial composition between healthy individuals and RA patients point to the role of gut microbiota in modulating immune responses and promoting inflammation. Therapies targeting microbiota restoration have demonstrated promise in improving treatment efficacy, enhancing patient outcomes and slowing disease progression. However, the complex interplay between gut microbiota and autoimmune pathways in RA requires further investigation to establish causative relationships and mechanisms. Here, we review the current understanding of the gut microbiota's role in RA pathogenesis and its potential as a therapeutic target.
类风湿关节炎（RA）是一种慢性自身免疫性疾病，会导致关节炎症、进行性组织损伤和严重残疾，严重影响患者的生活质量。虽然RA的确切发病机制尚不清楚，但越来越多的证据表明肠道微生物群失调与该疾病的发生和发展之间存在密切联系。健康个体与RA患者之间微生物组成的差异表明肠道微生物群在调节免疫反应和促进炎症方面的作用。针对微生物群恢复的疗法已显示出有望提高治疗效果、改善患者预后并减缓疾病进展。然而，RA中肠道微生物群与自身免疫途径之间复杂的相互作用需要进一步研究，以确定因果关系和机制。在此，我们综述了目前对肠道微生物群在RA发病机制中的作用及其作为治疗靶点的潜力的理解。
